Originally established as a private investment vehicle associated with a European entrepreneurial family, over the past two decades, Orchis has participated in the creation, financing and growth of numerous biotechnology, pharmaceutical and medical technology companies.

Today, Orchis combines investment with selected venture development activities, managing intellectual property, technology assets and early-stage projects originating from previous investments and scientific collaborations. Current activities focus particularly on antimicrobial resistance, infectious diseases, metabolic health and longevity across human and animal health.

A distinguishing characteristic of Orchis is its ability to bring together scientific expertise, entrepreneurial experience and international partnerships. Orchis works with an international network of academic researchers, industry experts and strategic partners across Europe, Africa, Asia and Latin America to evaluate technologies, structure development projects and establish pathways towards financing and commercialization.

Beyond Life Sciences, Orchis may selectively invest in emerging technologies and other opportunities with attractive long-term value creation potential.

Orchis pursues a long-term strategy based on disciplined capital allocation, active involvement and the translation of promising innovation into investable technologies, products and businesses.

The ultimate objective is not only to generate sustainable financial returns but also to develop technologies and therapies that make a measurable difference to human and animal health worldwide.